SG11201808388QA - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith - Google Patents
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithInfo
- Publication number
- SG11201808388QA SG11201808388QA SG11201808388QA SG11201808388QA SG11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA
- Authority
- SG
- Singapore
- Prior art keywords
- san diego
- international
- compositions
- co7d
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173206 Al 5 October 2017 (05.10.2017) WIPO I PCT 111111111111110111010101111101011111011101011111011101011011111111111111110111111 (51) International Patent Classification: A61K 31/52 (2006.01) CO7D 473/02 (2006.01) A61K 31/505 (2006.01) CO7D 473/26 (2006.01) A61K 31/519 (2006.01) CO7D 473/32 (2006.01) (21) International Application Number: PCT/US2017/025252 (22) International Filing Date: 31 March 2017 (31.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/317,412 1 April 2016 (01.04.2016) US (71) Applicant: SIGNAL PHARMACEUTICALS, LLC [US/US]; 10300 Campus Point Drive, Suite 100, San Diego, CA 92121 (US). (72) Inventors: BOYLAN, John, F.; 10486 Harvest View Way, San Diego, CA 92128 (US). BRAY, Gordon, L.; 301 Main Street, Unit 8c, San Francisco, CA 94105 (US). FILVAROFF, Ellen; 538 18th Avenue, San Francisco, CA 94121 (US). HUBBARD, Robert; 7684 Marker Road, San Diego, CA 92087 (US). MIKOLON, David; 6140 Calle Empinada, San Diego, CA 92120 (US). RAYMON, Heather; 3520 Vista de la Orilla, San Diego, CA 92117 (US). SHI, Tao; 4650 Tarantella Lane, San Diego, CA 92130 (US). TRAN, Tam, M.; 8953 Libra Drive, San Diego, CA 92126 (US). TSUJI, Toshiya; 4171 Donald Court, San Diego, CA 92117 (US). WONG, Lilly, L.; 871 Viva Court, Solana Beach, CA 92075 (US). XU, Suichan; 9650 Deer Trail Place, San Diego, CA 92127 (US). ZHU, Dan; 4432 Calle Mar De Armonia, San Diego, CA 92130 (US). (74) Agents: BRUNER, Michael, J. et al.; Jones Day, 250 Ve- sey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, [Continued on next page] (54) Title: SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH (57) : Provided herein are methods for treating or preventing a cancer, including solid tumors and hematologic- al cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds. (I) W O 20 1717 / 3 206 Al FIG. 1 WO 2017/173206 Al MIDEDIMOMOIDEIRMEMOMMEIIMMIMERVOIMIE NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317412P | 2016-04-01 | 2016-04-01 | |
| PCT/US2017/025252 WO2017173206A1 (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808388QA true SG11201808388QA (en) | 2018-10-30 |
Family
ID=59959573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808388QA SG11201808388QA (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| SG10202009589UA SG10202009589UA (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009589UA SG10202009589UA (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10576085B2 (en) |
| EP (1) | EP3436018A4 (en) |
| JP (1) | JP7014731B2 (en) |
| KR (1) | KR102356433B1 (en) |
| CN (1) | CN109069512B (en) |
| AU (1) | AU2017241837B2 (en) |
| BR (1) | BR112018070163A2 (en) |
| CA (1) | CA3018986A1 (en) |
| CL (1) | CL2018002787A1 (en) |
| EA (1) | EA039392B1 (en) |
| IL (1) | IL262007B2 (en) |
| MX (1) | MX2018011992A (en) |
| NZ (1) | NZ746554A (en) |
| SG (2) | SG11201808388QA (en) |
| WO (1) | WO2017173206A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| HRP20231681T1 (en) | 2015-11-02 | 2024-04-12 | Blueprint Medicines Corporation | Inhibitors of ret |
| BR112018068676A2 (en) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | substituted indole derivatives as dengue viral replication inhibitors |
| MX2018011788A (en) | 2016-03-31 | 2019-05-20 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors. |
| MA44502A (en) | 2016-04-01 | 2019-02-06 | Janssen Pharmaceuticals Inc | SUBSTITUTE INDOLE DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS |
| RS62496B1 (en) | 2016-04-01 | 2021-11-30 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| MA48943A (en) | 2017-05-22 | 2021-04-28 | Janssen Pharmaceuticals Inc | SUBSTITUTE INDOLINE DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS |
| JP7179773B2 (en) | 2017-05-22 | 2022-11-29 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Substituted Indoline Derivatives as Dengue Virus Replication Inhibitors |
| AU2018345647A1 (en) | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
| MX2020010417A (en) | 2018-04-03 | 2021-01-08 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration. |
| JP2021534129A (en) * | 2018-08-10 | 2021-12-09 | ブループリント メディシンズ コーポレイション | Treatment of EGFR mutant cancer |
| JP2022529642A (en) * | 2019-04-16 | 2022-06-23 | ビバーチェ セラピューティクス，インク． | Bicyclic compound |
| WO2021102204A1 (en) * | 2019-11-20 | 2021-05-27 | Vivace Therapeutics, Inc. | Heteroaryl compounds |
| CN115916747A (en) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | Fused heterocyclic derivative and application thereof in medicine |
| CN114681456A (en) * | 2022-02-23 | 2022-07-01 | 中山大学附属第六医院 | Use of PLX3397 in the treatment of colorectal cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (en) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | DNA encoding multipotent granulocyte colony stimulating factor |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes |
| FI109088B (en) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tablet and process for its preparation |
| CA2548326A1 (en) | 2003-12-23 | 2005-07-14 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
| US7521446B2 (en) * | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US20070225304A1 (en) * | 2005-09-06 | 2007-09-27 | Pharmacopeia Drug Discovery, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| JP2009516707A (en) | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | Solid preparation |
| WO2007134298A2 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| TWI398252B (en) | 2006-05-26 | 2013-06-11 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| CA2667345C (en) | 2006-10-27 | 2016-03-22 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| ES2400006T3 (en) | 2008-04-23 | 2013-04-04 | Farmasierra Manufacturing, S.L. | Enhanced pharmaceutical formulation based on ibuprofen and codeine |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US9466042B2 (en) | 2012-01-24 | 2016-10-11 | International Business Machines Corporation | Facilitating the design of information technology solutions |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| SI3204386T1 (en) * | 2014-10-06 | 2021-08-31 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| CN105184228A (en) * | 2015-08-13 | 2015-12-23 | 小米科技有限责任公司 | Mobile device and screen module thereof, fingerprint acquisition method and apparatus, and electronic device |
| RS62496B1 (en) * | 2016-04-01 | 2021-11-30 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use |
-
2017
- 2017-03-31 WO PCT/US2017/025252 patent/WO2017173206A1/en active Application Filing
- 2017-03-31 EP EP17776735.7A patent/EP3436018A4/en active Pending
- 2017-03-31 NZ NZ746554A patent/NZ746554A/en unknown
- 2017-03-31 JP JP2018551358A patent/JP7014731B2/en active Active
- 2017-03-31 SG SG11201808388QA patent/SG11201808388QA/en unknown
- 2017-03-31 CN CN201780021651.0A patent/CN109069512B/en active Active
- 2017-03-31 MX MX2018011992A patent/MX2018011992A/en unknown
- 2017-03-31 KR KR1020187028514A patent/KR102356433B1/en active IP Right Grant
- 2017-03-31 BR BR112018070163A patent/BR112018070163A2/en not_active Application Discontinuation
- 2017-03-31 CA CA3018986A patent/CA3018986A1/en not_active Abandoned
- 2017-03-31 SG SG10202009589UA patent/SG10202009589UA/en unknown
- 2017-03-31 US US15/475,899 patent/US10576085B2/en active Active
- 2017-03-31 AU AU2017241837A patent/AU2017241837B2/en active Active
- 2017-03-31 EA EA201892229A patent/EA039392B1/en unknown
- 2017-03-31 IL IL262007A patent/IL262007B2/en unknown
-
2018
- 2018-09-28 CL CL2018002787A patent/CL2018002787A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10576085B2 (en) | 2020-03-03 |
| CA3018986A1 (en) | 2017-10-05 |
| NZ746554A (en) | 2023-03-31 |
| KR20180126497A (en) | 2018-11-27 |
| SG10202009589UA (en) | 2020-10-29 |
| EP3436018A1 (en) | 2019-02-06 |
| JP7014731B2 (en) | 2022-02-01 |
| WO2017173206A1 (en) | 2017-10-05 |
| AU2017241837B2 (en) | 2021-07-22 |
| JP2019510066A (en) | 2019-04-11 |
| CN109069512A (en) | 2018-12-21 |
| EA039392B1 (en) | 2022-01-21 |
| AU2017241837A1 (en) | 2018-10-25 |
| MX2018011992A (en) | 2019-01-24 |
| IL262007B2 (en) | 2023-04-01 |
| KR102356433B1 (en) | 2022-01-27 |
| CN109069512B (en) | 2022-06-14 |
| IL262007A (en) | 2018-10-31 |
| EP3436018A4 (en) | 2019-11-13 |
| BR112018070163A2 (en) | 2019-01-29 |
| EA201892229A1 (en) | 2019-03-29 |
| US20170281633A1 (en) | 2017-10-05 |
| CL2018002787A1 (en) | 2019-01-18 |
| IL262007B (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808388QA (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808003RA (en) | Bromodomain inhibitors | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201903193WA (en) | Deodorant comprisng a zinc carboxylate salt and aluminium chlorohydrate | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |